Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

An Interview with Expert Clinician Dr. Fred Wigley

Jason Liebowitz, MD, FACR  |  Issue: January 2024  |  January 10, 2024

Rheumatologists who are outstanding researchers, educators and/or clinicians, who provide consistently exceptional care to patients, who have achieved a level of  distinction in the field and who serve as role models for colleagues and trainees are highlighted in this recurring series.

Fred Wigley, MD, MACR, is the Martha McCrory Professor of Medicine at the Johns Hopkins University School of Medicine, Baltimore. In 1990, Dr. Wigley established the Johns Hopkins Scleroderma Center to provide excellent care to patients with scleroderma, Raynaud’s phenomenon and related disorders; to perform clinical and basic science research; and to provide educational opportunities. His primary research interest is in scleroderma, Raynaud’s phenomenon and related disorders. He has published more than 180 peer-reviewed manuscripts. He has served as co-editor of Arthritis & Rheumatology, and he has co-edited the books Scleroderma: From Pathogenesis to Comprehensive Management and Raynaud’s Phenomenon: A Guide to Pathogenesis and Treatment. In 2009, Dr. Wigley received the ACR Distinguished Clinician Scholar Award and, in 2011, he was named an ACR Master.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

TR: In your opinion, what makes an expert clinician?

Dr. Wigley: When I first started my rheumatology career, I would accept any request. In this phase of my career, I focus on scleroderma, a chronic disease that can shorten one’s life, cause terrible disability and alter the body’s appearance.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

I like to start the patient encounter without any preceding information that may influence my judgment. I usually start the visit with some non-medical conversation to relax the visit. The evaluation of the patient starts as soon as the face-to-face encounter begins, and I use my senses to characterize the patient: sick or not sick, nervous or calm, sad or happy, etc. I open the interview with an open question and then listen.

I then try to refine the facts by getting all the fine details of the patient’s symptoms. It is then important to me to review every system not already mentioned to unearth symptoms or signs that need attention or that interact with the principal concern. I then review records and previous medical facts to set the scene for the examination.

I ask the patient to undress and get into a gown to do an exam focused on the main issue, but allowing me to carefully look for the unexpected.

Dr. Wigley

The final phase of the encounter is communication and making sure the patient understands the plan and intervention. I use pen and paper or printed pictures to illustrate my thoughts. This approach is used for new and return patients so each encounter is fresh.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:OpinionProfiles Tagged with:Dr. Fred WigleyRole Models in Rheumatology

Related Articles
    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    February 17, 2018

    The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Targeted Therapy for Scleroderma Fibrosis

    October 11, 2016

    Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a prevalence in North America of approximately 300 per 1 million people, SSc is associated with significant morbidity and high rates of mortality.1 Patients with scleroderma have four times greater mortality than age- and sex-matched controls, with…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences